论文部分内容阅读
目的:分别选用Ang-2、CA125、CA19-9和SCC检测妇科肿瘤患者及正常人群,以评估Ang-2在妇科肿瘤检测中的应用价值。方法:对256例妇科肿瘤患者(110例宫颈癌患者、77例卵巢癌患者、41例子宫内膜癌患者、28其它妇科肿瘤患者)和139例正常人群分别以免疫比浊法检测Ang-2,微粒子酶免疫测定法检测SCC,电化学发光法法检测CA125、CA19-9。结果:Ang-2、CA125、CA19-9、SCC在妇科肿瘤患者中的检出率分别为68.0%、43.4%、37.1%和37.5%;在正常人群中的检出率分别为1.4%、10.1%、11.5%和3.6%;其中Ang-2、CA125、CA19-9、SCC在宫颈癌患者中的检出率分别为67.3%、42.7%、39.1%、47.3%;在卵巢癌患者中的检出率分别为70.1%、58.4%、37.7%、31.2%;在子宫内膜癌患者中的检出率分别为68.3%、22.0%、29.3%、26.8%。经过CA125、CA19-9、SCC检测为阴性的卵巢癌患者,宫颈癌、子宫内膜癌患者再进行Ang-2检测,发现Ang-2对其它3种检测指标有很好的互补性,最低互补检出率48.3%。结论:Ang-2作为一种国际公认的实体肿瘤的广谱标志物,它相对于其它标志物在妇科肿瘤患者的早期筛查及临床辅助诊断方面都有着显著的优势,具有重要的临床价值。
Objective: To evaluate the value of Ang-2 in the detection of gynecological tumors by using Ang-2, CA125, CA19-9 and SCC respectively in gynecological cancer patients and normal subjects. Methods: Immuno-turbidimetry was used to detect Ang-2 in 256 gynecological cancer patients (110 cervical cancer patients, 77 ovarian cancer patients, 41 endometrial cancer patients, 28 other gynecologic cancer patients) and 139 healthy controls. SCC was detected by microparticle enzyme immunoassay and CA125 and CA19-9 were detected by electrochemiluminescence method. Results: The detection rates of Ang-2, CA125, CA19-9 and SCC in gynecologic oncology patients were 68.0%, 43.4%, 37.1% and 37.5% respectively. The detection rates in normal population were 1.4% and 10.1% %, 11.5% and 3.6%, respectively. The detection rates of Ang-2, CA125, CA19-9 and SCC in cervical cancer patients were 67.3%, 42.7%, 39.1% and 47.3% The rates were 70.1%, 58.4%, 37.7% and 31.2%, respectively. The detection rates in patients with endometrial cancer were 68.3%, 22.0%, 29.3% and 26.8% respectively. Ang-2 was detected in patients with cervical cancer and endometrial cancer after ovarian cancer patients with negative CA125, CA19-9 and SCC tests and found that Ang-2 had good complementarity with the other three detection indexes, with the lowest complementarity The detection rate was 48.3%. Conclusion: Ang-2 is an internationally recognized marker of broad spectrum of solid tumors. It has significant clinical value in early screening and clinical diagnosis of gynecologic oncology compared with other markers.